Resonance Health Ltd

Resonance Health operates with a debt-to-equity ratio of 0.4 and a current ratio of 1.28, indicating moderate liquidity risk despite negative net cash after subtracting total debt. The company reported negative free cash flow of -1.39 million AUD and capital expenditures of -622,900 AUD, suggesting ongoing investment in operations. Profitability metrics show a return on equity of -18.45% and a return on assets of -9.69%, both significantly below industry benchmarks for medical technology firms. These negative returns reflect the company's current unprofitable operations and underperformance relative to its sector. The company's revenue is concentrated across four segments: SaMD, Corporate, Resonance Clinical, and TrialsWest. The SaMD segment is the primary revenue driver, with products like FerriScan and HepaFatScan. However, the lack of geographic diversification and reliance on a limited number of products increases exposure to market-specific risks. Resonance Health reported revenue of 11.16 million AUD, but the outlook for the current fiscal year shows no significant growth. The company's operating income was -1.84 million AUD, and net income was -1.73 million AUD, indicating a challenging growth trajectory. The risk assessment highlights medium liquidity risk and low dilution potential. The company's negative free cash flow and capital expenditures suggest ongoing financial strain. No significant dilution events were identified in recent filings, but the company's financial position remains vulnerable. Recent filings and transcripts indicate the company is focused on expanding its SaMD product portfolio and maintaining its role as a clinical trial research organization. However, the lack of positive earnings and cash flow generation remains a concern for investors.